{{Rsnum
|rsid=4299376
|Gene=ABCG8
|Chromosome=2
|position=43845437
|Orientation=plus
|GMAF=0.1726
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=ABCG8
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 6.2 | 45.1 | 48.7
| HCB | 0.0 | 1.5 | 98.5
| JPT | 0.0 | 0.0 | 100.0
| YRI | 4.8 | 20.4 | 74.8
| ASW | 7.1 | 16.1 | 76.8
| CHB | 0.0 | 1.5 | 98.5
| CHD | 0.0 | 0.9 | 99.1
| GIH | 5.0 | 37.6 | 57.4
| LWK | 4.6 | 31.5 | 63.9
| MEX | 1.7 | 29.3 | 69.0
| MKK | 6.5 | 21.4 | 72.1
| TSI | 7.8 | 47.1 | 45.1
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4299376
|Name_s=
|Gene_s=ABCG8, ABCG5
|Feature=
|Evidence=PubMed ID:17632509
|Annotation=In a case-control study of European populations, rs4299376 was found to be associated with risk of gallstones.
|Drugs=
|Drug Classes=
|Diseases=Cholelithiasis
|Curation Level=Curated
|PharmGKB Accession ID=PA162356131
}}

{{PMID Auto GWAS
|PMID=20686565
|Trait=None
|Title=Biological, clinical and population relevance of 95 loci for blood lipids.
|RiskAllele=G
|Pval=0
|OR=2.7500
|ORtxt=None
|OA=1
}}

{{PMID Auto
|PMID=19060906
|Title=Common variants at 30 loci contribute to polygenic dyslipidemia.
|OA=1
}}

{{PMID Auto
|PMID=19913121
|Title=Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4299376
|overall_frequency_n=96
|overall_frequency_d=126
|overall_frequency=0.761905
|n_genomes=51
|n_genomes_annotated=0
|n_haplomes=85
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23707316
|Title=High intestinal cholesterol absorption is associated with cardiovascular disease and risk alleles in ABCG8 and ABO: evidence from the LURIC and YFS cohorts and from a meta-analysis
}}

{{PMID Auto
|PMID=23100282
|Title=Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}